Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented new preclinical data from its immuno-oncology portfolio at the American Association for Cancer Research Annual Meeting 2026 in San Diego, including one oral and two poster sessions. The company reported findings that support the potential of TNX-1700 in reducing inflammation and tumor progression in gastric cancer models, as well as demonstrating favorable pharmacokinetics. TNX-4700 showed promising in vitro activity targeting BTLA, underscoring its potential as a cancer immunotherapy candidate, either alone or in combination with other checkpoint inhibitors.
The data presentations at AACR, a premier oncology conference, highlight Tonix's expanding focus beyond its central nervous system (CNS) franchise into immuno-oncology. The company is a fully-integrated, commercial-stage biotechnology company with a CNS commercial infrastructure supporting marketed products such as TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years, and acute migraine products Zembrace SymTouch and Tosymra. Tonix is also advancing Phase 2 clinical trials for TONMYA in major depressive disorder and acute stress disorder, and its CNS pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome.
The new data on TNX-1700 and TNX-4700 are significant for the immuno-oncology field, as gastric cancer remains a high unmet medical need with limited treatment options. TNX-1700's ability to reduce inflammation and tumor progression could offer a novel therapeutic approach. TNX-4700's activity against BTLA, an immune checkpoint, suggests it may enhance anti-tumor immune responses, particularly in combination with existing checkpoint inhibitors. These findings could impact the development of combination immunotherapies and provide new avenues for patients who do not respond to current treatments.
Beyond oncology, Tonix is advancing immunology programs including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. The company's diversified pipeline addresses multiple high-need areas, from CNS disorders to infectious diseases and transplant medicine.
Investors can follow the latest updates on Tonix Pharmaceuticals at the company's newsroom at https://ibn.fm/TNXP. The full press release detailing the AACR data is available at https://ibn.fm/Oly6o.
The presentation of these preclinical data at AACR underscores Tonix's commitment to addressing high unmet medical needs through innovative science. While TNX-1700 and TNX-4700 are investigational drugs, their potential to impact gastric cancer treatment and immunotherapy combinations makes them candidates to watch as they progress through development.
